Dr Swire met with Mr Al-Megrahi in Tripoli following a request by the Libyan man himself.

It was the first time the Scottish doctor has met Mr Al-Megrahi since the Libyan’s release. The two had previously met when the convicted bomber was in custody. Mr Al-Megrahi has kept a very low profile since his release, amid media speculation of his health and whereabouts.

Dr Swire was not expansive about the contents of his one-hour conversation with Mr Al-Megrahi, which he considers confidential, but was quick to quash media claims that the Libyan - who was given three months to live when released from a Scottish prison in August 2009 – was not really a dying man.

“Abdelbaset remains a sick man but he is in better shape than I had dared to hope. His mind is perfectly clear. I attribute this to the love and care of his family, especially his wife Aisha, the community, and to some extent also to the excellent medical care he seems to be receiving. This is a message of great cheer for all of us men, many of whom will sooner or later be victims of prostate cancer.”

Dr Swire said he decided to make the trip to Tripoli in solidarity with the man who still stands accused in the eyes of the law of killing the Scotsman’s daughter.

“We met as brother members of the human race and seekers of a common goal: the re-examination of the available evidence which led to a verdict we believe was reached under political pressure rather than the rules of justice.

“Abdelbaset does not want any further dealings with the media, believing he can do no more now that his appeal has been withdrawn.”

Mr Al-Megrahi maintained his innocence and his wish to see the verdict against him overturned, Dr Swire told The Sunday Times.

“That task now falls upon Scotland, and those who believe, like me, that the verdict was a miscarriage of justice.”

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.